Boothbay Fund Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Boothbay Fund Management’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-61,600	Closed	-$421K	–	2245
2022 Q1	$421K	Buy	+61,600	New	+$423K	0.01%	1397
2020 Q3	–	Sell	-860	Closed	-$695K	–	1037
2020 Q2	$695K	Buy	860 +418	+95%	+$3.69K	0.05%	486
2020 Q1	$351K	Buy	+442	New	+$3.4K	0.03%	530

Other funds holding AVDL

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Boothbay Fund Management's AVDL Position: Q2 2022 in Review

Boothbay Fund Management sold out of Avadel Pharmaceuticals (AVDL) in Q2 2022, closing a stake of 61,600 shares — an estimated $421K sold.

Boothbay Fund Management first reported a position in AVDL in Q3 2015 and held it in 5 quarters. The position peaked at $421K in Q1 2022. 82 funds tracked by Wall St. Rank hold AVDL as of Q2 2022.

Boothbay Fund Management reported no remaining Avadel Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Boothbay Fund Management sold 61,600 Avadel Pharmaceuticals shares in Q2 2022, an estimated $421K.
Boothbay Fund Management first reported a position in Avadel Pharmaceuticals in Q3 2015 and held it in 5 quarters.
Boothbay Fund Management's Avadel Pharmaceuticals position peaked at $421K in Q1 2022.
82 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2022.

Based on Boothbay Fund Management's 13F filing for Q2 2022, filed 15 Aug 2022.